MedTrace Logo

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05117489 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-08-19

No results posted yet for this study

Summary

This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

Miricorilant 150 mg

Miricorilant 150 mg for oral dosing

DRUG

Miricorilant 100 mg

Miricorilant 100 mg for oral dosing

DRUG

Miricorilant 50 mg

Miricorilant 50 mg for oral dosing

DRUG

Miricorilant 10 mg

Miricorilant 10 mg for oral dosing.

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Kavita Juneja, MD · Corcept Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-23
Primary Completion
2024-01-29
Completion
2024-01-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117489 on ClinicalTrials.gov